Charles River Laboratories | CRL - Debt


Charles River Laboratories reported $2.57B in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Agilent USD 3.35B 0 Dec/2025
Align Technology USD 114.45M 6.82M Dec/2025
Bio-Rad Laboratories USD 1.39B 9.2M Dec/2025
Bruker USD 2.04B 34.4M Dec/2025
Cardinal Health USD 8.92B 111M Mar/2026
Charles River Laboratories USD 2.57B 58.23M Dec/2025
Cigna USD 30.9B 563M Mar/2026
Concord Medical Services Hldg CNY 3.01B 27.15M Jun/2023
CVS Health USD 78.34B 13.78B Mar/2026
Danaher USD 18.48B 66M Mar/2026
Dentsply International USD 2.33B 137M Mar/2026
Elevance Health USD 31.84B 204M Mar/2026
Humana USD 13.99B 1.62B Mar/2026
Illumina USD 2.55B 23M Dec/2025
Incyte USD 39.43M 982K Mar/2026
Intrexon USD 0 13.82M Jun/2024
IQVIA Holdings USD 15.83B 109M Mar/2026
Laboratory Of America USD 6.53B 3.9M Dec/2025
Lakefront Biotherapeutics EUR 6.44M 480K Mar/2026
Lonza CHF 4.71B 915M Dec/2024
McKesson USD 8.62B 1.17B Dec/2025
Merck EUR 11.95B 152M Dec/2025
Mettler Toledo International USD 2.15B 57.69M Dec/2025
Novartis USD 47B 11.62B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Quest Diagnostics USD 6.41B 179M Mar/2026
Revvity USD 3.4B 29.2M Dec/2025
Thermo Fisher Scientific USD 39.39B 3.7B Dec/2025
United Therapeutics USD 200M 100M Mar/2025
UnitedHealth USD 77.92B 472M Mar/2026
Veradigm USD 200.33M 431K Sep/2022
Waters USD 1.49B 4.92M Dec/2025
West Pharmaceutical Services USD 202.8M 0 Mar/2026